Articles tagged "Immunosuppression"

2015 American Transplant Congress
Everolimus-Based Immunosuppression Is Associated With a Reduced Risk of New-Onset Malignancies After Liver Transplantation
P. De Simone,¹ P. Carrai,¹ L. Coletti,¹ D. Ghinolfi,¹ D. Campani,² F. Filipponi.¹
¹Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospital, Pisa, Italy; ²Pathology, University of Pisa Medical School Hospital, Pisa, Italy.
Background and aim: The inhibitor of the mammalian target of rapamycin (mTOR) everolimus (EVR) has shown anti-proliferative effects in experimental and clinical models. We investigated…
2015 American Transplant Congress
Aging Enhances Immunosuppressives Capacities of Tacrolimus By Functional Changes of CD4+ T-Cells
F. Krenzien,¹ M. Quante,¹ A. ElKhal,¹ H. Uehara,¹ R. Abdi,² B. Slegtenhorst,¹ H. Biefer,¹ S. Tullius.¹
¹Transplant Surgery Research Laboratory and Division of Transplant Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; ²Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Immunosenescence has broad consequences on alloimmunity and immunosuppression in the elderly may require age-adaptation. Here, we investigated the influence of aging on the effectivity of…
2015 American Transplant Congress
Customized Reminders and Provider Notification to Improve Adherence to Immunosuppression
P. Reese, R. Bloom, J. Trofe-Clark, A. Mussell, D. Leidy, S. Levsky, J. Zhu, Y. Lin, A. Troxel, H. Feldman, K. Volpp.
UPenn, Philadelphia, PA.
Background: Non-adherence to transplant immunosuppression is associated with an elevated risk of allograft loss. Novel, wireless-enabled pill bottles have created the opportunity to monitor patient…
2015 American Transplant Congress
Influence of POR*28 Genotype on Tacrolimus Disposition in Heart Transplant Recipients
T. Alford,¹ R. Page,¹ J. Lindenfeld,² C. Aquilante.¹
¹University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO; ²University of Colorado School of Medicine, Aurora, CO.
Polymorphisms in P450 oxidoreductase (POR) have been shown to modulate CYP3A activity and alter the pharmacokinetics of CYP3A substrates, such as tacrolimus (TAC). The objective…
2015 American Transplant Congress
The Use of Bortezomib for Desensitization in ABO Incompatible and Positive Crossmatch Kidney Transplant
J. Benken,¹ S. Akkina,² E. Benedetti.³
¹Pharmacy Practice, Univ. of IL-Chicago, Chicago, IL; ²Dept. of Medicine, Nephrology, Univ. of IL-Chicago, Chicago, IL; ³Dept. of Surgery, Univ. of IL-Chicago, Chicago, IL.
Introduction:ABO incompatible (ABOi) and positive crossmatch (PXM) living donor kidney transplantation is a life-saving alternative to dialysis. A variety of protocols exist utilizing plasmapheresis (PP)…
2015 American Transplant Congress
T-bet Directs nTreg Homing Into Draining Lymph Nodes by Regulation of Specific Migration and Adhesion Receptors
Y. Xiong, S. Ahmad, D. Iwami, C. Brinkman, J. Bromberg.
University of Maryland, Baltimore.
Background: The transcription factor T-bet endows Treg with the functional and migratory properties to suppress Th1 inflammation. Previously, we showed that nTreg homing into draining…
2015 American Transplant Congress
Pharmacokinetics of Tacrolimus (TAC) in Elderly Compared to Young Recipients in the First Year After Renal Transplantation. Data from the NEverOLd Trial
E. David-Neto,¹ P. Romano,² A. Triboni,¹ F. Agena,¹ P. Ebner,² F. Ramos,¹ N. Galante,¹ F. Lemos.¹
¹Renal Transplantation Service, Hospital das Clinicas – University of São Paulo School of Medicine, Sao Paulo, Brazil; ²Division of Central Laboratory, Hospital das Clinicas – University of São Paulo School of Medicine, Sao Paulo, Brazil.
Elderly (≥60years) recipients are nowadays receiving renal transplants more frequently. The pharmacokinetics studies (PK) of immunosuppressive drugs in healthy volunteers, rarely, if ever, include old…
2015 American Transplant Congress
Outcomes of Kidney Transplant Recipients Minimally Immunosuppressed: A Cohort Study Analysis
A.-H. Querard,^1,2,3 F. Gillaizeau,^2,1 G. Couvrat-Desvergne,^1,2,3 J. Dantal,^1,4,5 P. Daguin,¹ S. Le Floch,¹ S. Castagnet,⁶ S. Brouard,^1,4 Y. Foucher,^2,1 M. Giral.^1,2,4,5
¹Institute for Transplantation, Urology and Nephrology (ITUN), CHU Nantes, RTRS « Centaure », INSERM U1064, Université de Nantes, Nantes, France; ²EA 4275 SPHERE– Biostatistics, Pharmacoepidemiology and Human Sciences Research, Nantes University, Nantes, France; ³Centre Hospitalier Departemental de Vendée, La Roche sur Yon, France; ⁴Centre d'Investigation Clinique Biothérapie, Nantes, France; ⁵Centre Hospitalier Universitaire, Nantes, France; ⁶HLA Laboratory, Etablissement Français du Sang, Nantes, France.
Background: Renal transplantation is the treatment of choice for endstage renal disease. Nevertheless, it involves immunosuppressive treatments with Serious Adverse Events (SAE) such as infections…
2015 American Transplant Congress
No Significant Outcome Benefit for Brand-Name Versus Generic Tacrolimus in Kidney Transplant Recipients: SRTR Analysis
D. Goldfarb,¹ E. Poggio,¹ S. Flechner,¹ R. Fatica,¹ J. Schold.²
¹Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH; ²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH.
IntroGeneric formulations of tacrolimus have been available for maintenance immunosuppression since 2009. Our aim was to evaluate the frequency of use of generic tacrolimus and…
2015 American Transplant Congress
Significant Association Between Foxp3 Gene Polymorphism and Outcomes in HBV-Related Liver Transplant Patients
Y. Tanaka, V. Sapana, H. Ohdan.
Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Background: Previous studies have demonstrated that CD4+Foxp3+ regulatory T (Treg) cells regulate HBV-related disease progression. The present study investigated the association between Treg cells and…